The major histocompatibility complex class I polypeptide-related sequences A and B (MICA/B) are frequently expressed by cancer cells. In a recently published study, researchers from Icahn School of Medicine at Mount Sinai hypothesized that the therapeutic efficacy of anti-MICA/B antibodies could be enhanced through Fc optimization with three point mutations in the Fc region: G236A, A330L and I332E (GAALIE).